JP3981407B2 - 置換された０▲上６▼−ベンジルグアニン - Google Patents

置換された０▲上６▼−ベンジルグアニン Download PDF

Info

Publication number
JP3981407B2
JP3981407B2 JP50669496A JP50669496A JP3981407B2 JP 3981407 B2 JP3981407 B2 JP 3981407B2 JP 50669496 A JP50669496 A JP 50669496A JP 50669496 A JP50669496 A JP 50669496A JP 3981407 B2 JP3981407 B2 JP 3981407B2
Authority
JP
Japan
Prior art keywords
alkyl
amino
benzyl
group
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50669496A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10508288A (ja
Inventor
スィー． モシェル、ロバート
イー． ペッグ、アンソニー
ドラン、エム．アイリーン
ツェ、ミ−ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JPH10508288A publication Critical patent/JPH10508288A/ja
Application granted granted Critical
Publication of JP3981407B2 publication Critical patent/JP3981407B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50669496A 1994-08-01 1995-07-31 置換された０▲上６▼−ベンジルグアニン Expired - Lifetime JP3981407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/283,953 US5525606A (en) 1994-08-01 1994-08-01 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US283,953 1994-08-01
PCT/US1995/009702 WO1996004281A1 (en) 1994-08-01 1995-07-31 Substituted o6-benzylguanines and 6(4)-benzyloxypyrimidines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006273447A Division JP2007077157A (ja) 1994-08-01 2006-10-04 ６（４）−ベンジルオキシピリミジンおよび他の化合物

Publications (2)

Publication Number Publication Date
JPH10508288A JPH10508288A (ja) 1998-08-18
JP3981407B2 true JP3981407B2 (ja) 2007-09-26

Family

ID=23088285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50669496A Expired - Lifetime JP3981407B2 (ja) 1994-08-01 1995-07-31 置換された０▲上６▼−ベンジルグアニン
JP2006273447A Pending JP2007077157A (ja) 1994-08-01 2006-10-04 ６（４）−ベンジルオキシピリミジンおよび他の化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006273447A Pending JP2007077157A (ja) 1994-08-01 2006-10-04 ６（４）−ベンジルオキシピリミジンおよび他の化合物

Country Status (10)

Country Link
US (8) US5525606A (enExample)
EP (3) EP1142893B1 (enExample)
JP (2) JP3981407B2 (enExample)
AT (2) ATE207490T1 (enExample)
CA (2) CA2195856C (enExample)
DE (2) DE69523462T2 (enExample)
DK (2) DK1142893T3 (enExample)
ES (2) ES2167451T3 (enExample)
PT (2) PT1142893E (enExample)
WO (1) WO1996004281A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043228A (en) * 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
ES2253821T3 (es) * 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6060458A (en) * 1998-02-13 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6677345B1 (en) * 1998-03-28 2004-01-13 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
AU2002313673B2 (en) * 2001-02-08 2006-09-07 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
JP2005538134A (ja) * 2002-08-08 2005-12-15 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤
US7335654B2 (en) * 2002-08-08 2008-02-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE10307928A1 (de) * 2003-02-25 2004-09-16 Faustus Forschungs Cie. Translational Cancer Research Gmbh Verwendung von 1-(2-Chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur Behandlung von Pankreaskarzinomen, Weichteilsarkomen, Hodentumoren, Lymphomen, Thymomen, Wilms Tumoren, Nierenkarzinomen, Melanomen, Lungentumoren, intracerebralen Metastasen, Tumoren im Kopf- und Halsbereich, und Mamma-Karzinomen
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
CA2552826A1 (en) * 2004-01-06 2005-07-28 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services 2-amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase
ES2329595T3 (es) * 2004-05-12 2009-11-27 Bayer Cropscience Ag Regulacion del crecimiento de las plantas.
CA2579660A1 (en) * 2004-09-08 2006-03-16 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (The) Beta-glucuronidase cleavable prodrugs of o6-alkylguanine-dna alkyltransferase inactivators
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
AU2006230447A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
JP2008539198A (ja) * 2005-04-27 2008-11-13 コヴァリス・バイオサイエンシス・アーゲー Ｏ６−アルキルグアニン−ｄｎａアルキルトランスフェラーゼと反応するピリミジン
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
AU2007257423B8 (en) * 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
PL2125007T3 (pl) 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
WO2008137207A2 (en) * 2007-05-02 2008-11-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inactivators of o6-alkylguanine-dna alkyltransferase
US8542442B2 (en) 2007-05-07 2013-09-24 Centre Suisse d'Electronique et de Microtechnique SA—Recherche et Developpement Isotropic zero-order diffractive filter
KR20100137449A (ko) * 2008-02-07 2010-12-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 Ｔｌｒ７ 활성화제를 사용한 방광 질환의 치료
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) * 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
US20110305751A1 (en) 2009-02-20 2011-12-15 To-Bbb Holding B.V. Glutathione-based drug delivery system
AU2010245823B2 (en) 2009-05-06 2016-11-24 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120270812A1 (en) * 2009-08-24 2012-10-25 Duke University Compositions, methods, and kits for determining an alkyl transferase
CN101850504B (zh) * 2010-05-06 2011-11-16 陕西理工学院 一种用两个步进电机控制主轴运动的振动制孔装置
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
BR112013030442B1 (pt) * 2011-06-10 2021-11-09 Merck Patent Gmbh Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2014025749A2 (en) * 2012-08-06 2014-02-13 Sirga Advanced Biopharma, Inc. Small molecule inhibitors of viral protein interactions with human t-rna
ES2688194T3 (es) * 2014-09-11 2018-10-31 Bristol-Myers Squibb Company Inhibidores de mieloperoxidasa de triazolopirimidina y triazolopiridina de tioéter
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0184473A1 (en) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4801710A (en) * 1984-10-26 1989-01-31 Merck & Co., Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
US5723609A (en) * 1988-03-30 1998-03-03 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl purines
US5091430A (en) * 1990-03-13 1992-02-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels
US5691307A (en) * 1990-03-13 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services O6 -substituted guanine compositions and methods for depleting O6
US5352669A (en) * 1990-03-13 1994-10-04 The Of The United States Of America As Represented By The Department Of Health And Human Services O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity
WO1992000335A1 (en) * 1990-06-29 1992-01-09 Vinamul Limited Emulsion polymerisation
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US6043228A (en) 1993-06-08 2000-03-28 Cancer Research Campaign Technology Limited O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
WO1994029312A1 (en) 1993-06-08 1994-12-22 Cancer Research Campaign Technology Limited O6-substituted guanine derivatives, a process for their preparation and their use in treating tumour cells
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
ATE194920T1 (de) 1993-09-22 2000-08-15 Hoechst Ag Pro-prodrugs, ihre herstellung und anwendung
US5929046A (en) 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
SI0795334T1 (sl) 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1999025386A1 (en) 1997-11-13 1999-05-27 Case Western Reserve University delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE

Also Published As

Publication number Publication date
DE69533900T2 (de) 2005-12-29
CA2195856C (en) 2008-09-30
US20020013299A1 (en) 2002-01-31
ES2167451T3 (es) 2002-05-16
PT1142893E (pt) 2005-04-29
DK1142893T3 (da) 2005-03-29
EP1142893B1 (en) 2004-12-29
US6436945B2 (en) 2002-08-20
AU3207995A (en) 1996-03-04
JP2007077157A (ja) 2007-03-29
DE69523462T2 (de) 2002-07-11
JPH10508288A (ja) 1998-08-18
WO1996004281A1 (en) 1996-02-15
EP1518854A1 (en) 2005-03-30
US5753668A (en) 1998-05-19
US5916894A (en) 1999-06-29
US5525606A (en) 1996-06-11
ATE207490T1 (de) 2001-11-15
ATE286054T1 (de) 2005-01-15
US6172070B1 (en) 2001-01-09
CA2632452A1 (en) 1996-02-15
US5958932A (en) 1999-09-28
EP1142893A1 (en) 2001-10-10
EP0775142A1 (en) 1997-05-28
US6303604B1 (en) 2001-10-16
AU702711B2 (en) 1999-03-04
ES2233513T3 (es) 2005-06-16
DK0775142T3 (da) 2002-02-18
CA2195856A1 (en) 1996-02-15
PT775142E (pt) 2002-04-29
DE69523462D1 (de) 2001-11-29
EP0775142B1 (en) 2001-10-24
US6333331B1 (en) 2001-12-25
DE69533900D1 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
JP3981407B2 (ja) 置換された０▲上６▼−ベンジルグアニン
RU2325391C2 (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ И АМОРФНАЯ ФОРМА ТРИАЗОЛО[4,5-d]ПИРИМИДИНА
JP5323075B2 (ja) ４−ピリミジンスルファミド誘導体
CZ295234B6 (cs) Triazolo[4,5-d]pyrimidinové deriváty
GB1576351A (en) Xanthine derivatives
CS203093B2 (en) Method of preparing substituted purines
HU208832B (en) Process for producing purinylphosphonic acid derivatives and pharmaceutical compositions comprising same as active ingredient
CA1054521A (en) Biological materials
EP0077460B1 (en) Purine compounds endowed with immunomodulating activity
US5691307A (en) O6 -substituted guanine compositions and methods for depleting O6
US4027025A (en) 8-Azapurine derivatives
AU702711C (en) Substituted o6-benzylguanines and 6(4)-benzyloxypyrimidines
JPH066578B2 (ja) チアゾリジン誘導体
US5098905A (en) 7-deazaguanines as immunomodulators
US8188055B2 (en) Inactivators of O6-alkylguanine-DNA alkyltransferase
US4996319A (en) -2-Amino-4,6-dichloro-5-(2-cyanomethyl-2-amino-5(cyanomethyl)-4,6-dichloro pyrimidine
UA64697C2 (en) Platelet aggregation inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070702

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100706

Year of fee payment: 3